Merck agrees to acquire Verona Pharma for $10bn
Pharmaceutical Technology
JULY 10, 2025
How will RFK Jr’s American dream for vaccines play out? Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters. Give your business an edge with our leading industry insights.
Let's personalize your content